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This report summarises the surveillance of lead exposure in children in England from 1 January 
to 31 December 2019. 
 
A case is defined as a child: 
 
• with a blood lead concentration ≥0.48μmol/L (equivalent to ≥10μg/dl), as detected in 
a UK Accreditation Service (UKAS) accredited biochemistry or toxicology laboratory 
• reported to Public Health England (PHE) Health Protection Teams for public health 
intervention 
• aged under 16 years at the time of first elevated blood lead concentration 
• resident in England 
 
Main points 
• 36 cases of lead exposure in children were notified to PHE in 2019 
• most cases (83%) were directly notified to LEICSS by participating laboratories; 17% 
were notified to PHE through other routes 
• the median delay between a specimen being drawn and a case being entered onto 
HPZone for transfer to the local HPT to initiate public health action was 8 days 
• the number of cases detected was lower than the expected incidence of lead 
exposure based on international population survey data [7,8] 
• the average detection rate for England between 2015 and 2019 was 3.92 cases per 
million children aged 0 to 15 years, although there was large regional variation 
between PHE Centres 
• cases were typically 1 to 4 years of age, male, and resident in more deprived areas 
• the median blood lead concentration of cases was 0.65μmol/L (13.46 µg/dL) in 2019 
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Main messages and recommendations 
Lead is a persistent environmental contaminant that can cause toxicity even at low blood lead 
concentrations. There is no known safe lower threshold of exposure. 
 
Children exhibiting pica1 or hand to mouth behaviour in environments with lead hazards are 
likely at highest risk of exposure. 
 
Clinicians should be aware of important sources of lead exposure, children most at risk, and 
presenting symptoms or signs of exposure. 
 
Public Health England is proposing that the public health intervention level for lead is lowered 
from ≥10μg/dL (≥0.48μmol/L) to ≥5μg/dL (≥0.24μmol/L) for children under 16 years and for 
pregnant women; PHE is working with stakeholders to support this change and will advise from 
when these changes will take effect, which is anticipated in early 2021. 
 
Cases with a blood lead concentration above the public health intervention level for lead should 
be notified to PHE health protection teams for active public health case management. 
 
Progress on developing surveillance of lead cases has continued in 2020. PHE’s major efforts 
in health protection have focused on responding to the COVID-19 global pandemic. We have 
continued to respond to cases reported to PHE, but developments in surveillance functions 
have been delayed. 
  
 
1 The persistent ingestion of non-nutritive substances at an age where this is developmentally inappropriate. 
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At a time when the COVID-19 pandemic has impacted on all areas of our lives, and necessarily 
been the focus of most of Public Health England’s reactive and proactive efforts, it is important 
to remember that other preventable exposures such as lead continue to impact on human 
health. The laboratory reporting of lead exposure in children to LEICSS and the systematic 
onward notification of exposed children to health protection teams and their partners has 
continued throughout 2019 and 2020, maintaining a reduction in the time between identification 
of a high blood lead concentration and public health intervention. The collation of surveillance 
data presented in this annual report, under these difficult circumstances, provides evidence that 
this well-known hazard is still present across England, and confirms the need for us to continue 
with our efforts to try and reduce the impact of lead through early identification and timely 
intervention. 
 
Dr Araceli Busby 
 
Consultant in Health Protection 
 
Chair of the Lead Exposure in Children Surveillance System (LEICCS) steering and working 
groups 
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Exposure to lead can result in severe multi-system toxicity2. How this toxicity manifests depends 
on both the blood lead concentration (BLC), and how rapidly BLC rises. Overt manifestations of 
toxicity (that is, lead poisoning), such as anaemia or abdominal pain, accompany higher lead 
concentrations, for example, BLC>1.93μmol/L (>40µg/dl)3 [1]. Lead exposures resulting in a 
lower BLC may not cause such apparent symptoms, but still cause harm, particularly to the 
central nervous system. Decreased intellectual function and possibly other neuro-behavioural 
problems such as shortening of attention span and disruptive behaviour are associated with 
BLCs even below 0.48µmol/L (10µg/dl) [1,2]. Timely removal or abatement of the exposure 
source is the mainstay of case management, but symptomatic children, and children with blood 
lead concentration greater than 1.93μmol/L may also require chelation therapy [2]. 
 
Successful primary prevention efforts – targeted at reducing the use of lead in paints and fuels, 
regulation of lead concentrations in drinking water, planning controls and remediation of lead in 
soil, and control of industry emissions – have been successful in reducing BLC in children, as 
has been demonstrated in the USA [2]. However, lead is a persistent contaminant, therefore 
children can still be exposed to lead already in the environment. Since the removal of lead from 
petrol, ingestion rather than inhalation has been the most common route of exposure in high 
income countries, particularly from flakes and dust from exposed leaded paint [2]. Leaded paint 
had wide domestic use in the UK before gradual withdrawal from the 1960s onwards [3] and 
was banned for sale in 1992. 
 
Children with developmental disorders have been found to have higher blood lead 
concentrations than other children [4]; such children are at higher risk of exposure due to 
increased mouthing (or ‘pica’) behaviour [5] leading to increased ingestion of lead from paint 
flakes, lead in soil, and so on. Iron deficiency may further increase susceptibility to lead toxicity 
[6]. Other important potential routes of exposure in children are ingestion of lead-contaminated 
water, contaminated soil or dust, herbal medicine preparations, contaminated food, consumer 
products not meeting regulatory standards (for example, paint on toys, make-up, lead crystal 
glassware) or inhalation from lead-containing fuel emissions or secondary exposure from 
parental hobbies or occupations (for example, resulting in children being exposed to lead dust 
on work-clothing) [1]. 
 
There are no recent comprehensive survey data estimating how many children in England are 
exposed to lead. Recent estimations by the Institute of Health Metrics, using the Global Burden 
of Disease tools suggest that for the UK there are 213,702 (95% CI 186,117 to 281,542) 




3 Both µmol/L and µg/dL units are commonly used internationally to express blood lead concentrations, where 1 
µg/dl = 0.0483µmol/L. Divide the concentration in µg/dl by 20.7 to obtain the concentration in µmol/L. 
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42,470) children with BLC ≥0.48µmol/L (≥10µg/dl) in 2019. International population survey data 
may also be used for estimates; a survey conducted in France in 2008/20094 [7] estimated 
0.09% of 1 to 6 year-olds had a BLC ≥0.48µmol/L (≥10µg/dl), and 1.5% a BLC ≥0.24µmol/L 
(≥5µg/dl). A survey in the USA in 2013/14 [8] estimated 0.5% of 1 to 5 year olds had a BLC 
≥0.24µmol/L (≥5µg/dl). Comparison with historic data strongly suggests a substantial fall in 
average BLCs [8]. However, population lead exposure is strongly influenced by setting, so these 
findings give only a broad indication of the potential situation in England. 
 
Lead exposure is diagnosed by a blood test to measure the blood lead concentration. Because 
signs and symptoms of lead exposure are non-specific, an evidence review for population 
screening was carried out by the National Screening Committee in 2018. A systematic 
population screening programme was not recommended [9] because of concerns about testing 
and treatment and the lack of up to date population data (alongside evidence of a steady 
decline in lead exposure over time). Case detection therefore depends on clinicians having a 
high clinical suspicion, for example due to the home circumstances of the child increasing the 
risk of lead exposure, and subsequently ordering a blood test. Surveillance of cases identified 
by clinicians offers a means of gathering intelligence to guide public health action to prevent 
further cases of exposure. 
 
The Lead Exposure in Children Surveillance System 
(LEICSS) 
PHE coordinates LEICSS, a national surveillance system for children resident in England. 
Formal surveillance of lead exposure in children in England was initiated in 2010 by the 
Surveillance of Raised Blood Lead Levels in Children (SLiC) study, a joint research project 
between the British Paediatric Surveillance Unit and the Health Protection Agency (the forebear 
to PHE). The SLiC study authors recommended implementation of a laboratory-based 
surveillance system in order to facilitate timely public health management of cases of lead 
poisoning in children [10]. A pilot system, the Lead Poisoning in Children (LPIC) surveillance 
system, was therefore instigated in 2014. LPIC was then permanently implemented in 2016 
following successful evaluation of the pilot, and its name changed to LEICSS to recognise 
broader aims of prevention of lead exposure in children, in addition to the rapid recognition of 
cases of lead poisoning. 
 
A PHE working group oversees LEICSS management, and a steering group with additional 
representatives from participating laboratories, academia, NHS clinical toxicology and patient 
groups oversee system aims and development (see Steering and Working Group Members 
below). LEICSS is one component of the Environmental Public Health Surveillance System 
 
4 France banned white lead-based interior paint in 1909 (earlier than England); thus exposures from this source 
would be expected to be lower than in the UK. 
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(EPHSS) operated by PHE as part of Environmental Public Health Tracking, and the steering 
group and working group report to the PHE Environmental Public Health Tracking Board.  
More information about Environmental Public Health Tracking and EPHSS 
 
LEICSS aims are: 
 
• to facilitate timely public health action for individual cases, as the mainstay of 
treatment for cases of lead exposure is rapid removal of the putative source of 
exposure 
• the system should also meet population level surveillance objectives, to inform public 
health action to reduce the incidence of lead exposure in children in England, such 
as by identifying at risk geographic areas or populations, and identification of current 
and emerging sources of exposure 
 
Case reporting to LEICSS 
LEICSS is a passive surveillance system that integrates reports of incident (newly detected) 
cases of lead exposure in children from 2 sources: 
 
• cases reported to PHE directly from a testing biochemistry or toxicology laboratory, 
or  
• searching HPZone5 for cases first reported from a non-PHE source (for example, the 
managing clinician or an environmental health officer) to a local PHE Health 
Protection Team (HPT)6, or from other PHE departments (for example, PHE CRCE 
Environmental Hazards and Emergencies department) and not reported to LEICSS 
by laboratories participating in surveillance 
 
Case notification to PHE is voluntary but encouraged for case management and surveillance 
purposes. 
 
Case reports from biochemistry and toxicology laboratories  
Reports of cases meeting the following case definition are referred to as ‘laboratory-detected’ 
cases. A laboratory-detected case is defined as a child: 
 
• with a blood lead concentration ≥0.48μmol/L (equivalent to ≥10μg/dl), as detected in 
a UK Accreditation Service (UKAS) accredited biochemistry or toxicology laboratory 
• aged under 16 years at the time of first elevated blood lead concentration 
• resident in England 
 
 
5 HPZone is the public health case management system used in England by PHE Health Protection Teams when 
investigating and managing public health threats to their local populations. 
6 HPTs are frontline units responsible for investigating and managing public health threats to their populations. 
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LEICSS surveillance staff enter case details onto HPZone following notification. The relevant 
local HPT is then alerted to investigate and manage the case. This route of notification to the 
investigating HPT has been found to be timelier than waiting for notification from other sources 
involved in treating the case, for example, the managing clinician [11]. 
 
‘HPZone-detected’ cases 
HPZone-detected cases are those that are or were: 
 
• managed as cases diagnosed with ‘toxic exposure to lead’ by a health protection 
team based in England 
• aged under 16 years at the time of notification to the health protection team 
• resident in England 
• not initially notified to LEICSS by a participating biochemistry or toxicology laboratory 
 
Blood lead concentration data are not routinely recorded on HPZone in a way that makes them 
available for analyses by LEICSS for these cases. 
 
The Supra-regional Assay Service (SAS) Trace Elements laboratories 
network, and other reporting laboratories 
A group of highly specialised diagnostic laboratories, the SAS, provide a referral network for 
specialised laboratory investigations in the UK. Blood lead concentration is measured in 6 SAS 
Trace Elements laboratories in England, and it is estimated they perform the vast majority of 
such tests nationally. All 6 SAS laboratories participate in LEICSS, and a partnership between 
the SAS-associate laboratory in Wales (Cardiff Toxicology Laboratory) has been developed to 
alert LEICSS of England residents whose blood lead concentration may be determined in 
Cardiff. Other, non-SAS but UKAS accredited laboratories have also agreed to report cases to 
LEICSS; these are typically located in larger NHS Trusts or are private laboratories. 
 
Public health management of cases 
A BLC of ≥0.48μmol/L (or ≥10μg/dl) is the current threshold (‘public health intervention level’) for 
public health case management in England. HPTs will take steps to systematically identify and 
remove the potential source(s) of lead exposure in cases, following guidance in the PHE Lead 
Action Card [12]. This involves liaison and involvement with other PHE stakeholders, such as 
the Environmental Hazards and Emergencies department, and non-PHE stakeholders, such as 
the responsible clinician and local authority where the case resides. General information on lead 
and incident management (updated August 2019, with further updates due when the public 
health intervention level changes) can be found on the PHE website.  
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Purpose of this report 
This report provides a summary of data extracted from the national LEICSS dataset for cases of 
child lead exposure in residents of England reported to Health Protection Teams during 1 
January to 31 December 2019. As the number of cases in each year is small, we have 
compared the 2019 metrics to the previous 2015 to 2018 4-year average, where relevant, using 
data from cases with report dates between 1 January to 31 December for each of these years. 
 
Figures are correct at the time of publication and may be subject to change as new information 
about cases becomes available.  
 
You can read this report and previous year’s annual report and other surveillance reports. 
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Surveillance data indicators 
 
Detection of cases of lead exposure in children in 
England, and support for timely case notification for 
public health action 
Number of unique cases 
There were 36 unique cases detected in 2019 that met the case definition. Eighty-three percent 
of cases were direct laboratory reports to LEICSS, similar to the 2015 to 2018 average of 81% 
(Table 1). Figure 1 shows the number of cases report per year 2015 to 2019, England.  
 
Table 1. Count and percentage of LEICSS cases, by reporting route to LEICSS, England 
2019, and 2015 to 2018 
 
Route of detection 
by LEICSS 
Count of cases 2019* 
(% of total) 
Count of cases* 2015 to 2018 
(% of total) 
Direct laboratory 
reports 30 (83) 129 (81) 
HPZone search 6 (17) 31 (19) 
Total 36 160 
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Figure 1. Count of LEICSS cases, England 2015 to 2019 
 
Timeliness of reporting of lab-detected cases to LEICSS and notification 
of Health Protection Teams 
For the laboratory detected cases, the median delay between the date of specimen collection 
and the date the case was entered onto HPZone (as a proxy for date of report to HPTs) was 8 
days, consistent with the 2015 to 2018 median of 9 days (Table 2).  
 
Table 2. Time between specimen collection and entry of case onto HPZone for case 
management for lab-detected LEICSS cases, England 2019, and 2015 to 2018 
 
Year Cases Cases with valid data* Median days delay LQ - UQ 
2019 30 28 8 7-14 
2015 to 
2018 129 124 9 7-14 
* Cases where both a valid specimen date and a valid date of entry onto to HP Zone were extracted from HPZone; 









2015 2016 2017 2018 2019
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Occurrence and trends of cases of lead exposure in 
children 
Count and detection rate (by LEICSS) of cases by PHE Centre and 
year 
The number of cases detected in 2019 decreased slightly compared to 2018 and 2017 (Table 
3). However, since there is significant under-ascertainment of cases. this should not be 
interpreted as a reduction in incidence (see following section on ascertainment). The largest 
reduction in case detection was observed in the West Midlands in 2019 (0 cases detected 
compared to 4 in 2018) (Fig 2). This lack of detection could be explained by laboratory staff 
shortages that occurred in 2019. Case detection increased in Yorkshire and the Humber and 
the North West but declined in the remaining regions. The average detection rate for England 
between 2015 and 2019 was 3.92 cases per million children aged 0 to 15 years, although there 
was large regional variation; the detection rate was 15 times higher in Yorkshire and Humber 
(15.18 cases per million) compared to the North East and East Midlands (1.06 cases per million 
and 1.41 cases per million) (Table 3, Figures 2 and 3).  
 
Variation in case detection over time and place is more likely to be due to differences in 
awareness among clinicians, testing of children at risk and reporting by laboratories, rather than 
a change in the number of children exposed to lead hazards. Additionally, the total cases each 
year is relatively small, and is therefore prone to change due to random variation, meaning 
longer-term observation is required to confirm a trend. 
 
The case detection rate and ascertainment 
Because lead exposure below the level causing overt toxicity commonly causes few or non-
specific symptoms, surveillance of clinically reported cases is likely to under ascertain the 
number of affected children. International population surveys, which more accurately estimate 
the number of children exposed to lead, suggest an expected incidence of cases of paediatric 
lead exposure higher than detected through LEICSS [7,8]. The figures above should not 
therefore be considered representative of the incidence of child lead exposure in England.  
Factors affecting case ascertainment are also likely to be driving the variation seen between 
regions. For instance, PHE are aware of a system introduced by Leeds SAS laboratory (based 
in Yorkshire and Humber) to actively prompt clinicians to consider testing for lead exposure in 
children whose blood is being tested for suspected iron deficiency, where that child is also 
known to have pica [13]. There is also active engagement of local clinicians by this laboratory. 
The 90% increase in testing and case reporting in this region following the introduction of this 
system demonstrates that differences in clinician awareness and testing rate strongly influence 
case ascertainment by the surveillance system (and potentially more than differences in the 
frequency of lead hazards in the environment between regions). Testing of cases in laboratories 
not reporting cases to LEICSS may also explain part of the regional variation in case 
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ascertainment, though it is expected SAS labs perform the large majority of BLC tests in 
children in England. Non-reporting of cases by participating laboratories may also have (more 
rarely) occurred. Irregular case entry onto HPZone may have prevented some cases being 
detected by our search, though cases first notified to LEICSS are entered using a standard 
procedure. Estimating area-specific testing rates would aid the interpretation of case detection 
rates but is difficult given the supra-regional catchment of SAS laboratories. 
 
Table 3. Count and percentage of LEICSS cases, and average detection rate† of cases 
(per million 0 to 15 year old children) by PHE Centre and year of notification, England 




















Average detection rate‡ 
of cases (per million per 
year) 2015 to 2019 
South 
East* 6 (18) 0 (0) 4 (8) 3 (7) 1 (3) 14 (7) 2.09 
London* 5 (15) 7 (21) 10 (20) 12 (27) 11 (31) 45 (23) 6.21 
South 
West 2 (6) 0 (0) 2 (4) 4 (9) 2 (6) 10 (5) 4.47 
West 
Midlands* 2 (6) 3 (9) 3 (6) 4 (9) 0 (0) 12 (6) 2.61 
East 
Midlands 1 (3) 0 (0) 0 (0) 3 (7) 1 (3) 5 (3) 1.41 
North 
West 4 (12) 6 (18) 11 (22) 3 (7) 4 (11) 28 (14) 7.63 




9 (27) 12 (36) 16 (33) 12 (27) 14 (38) 63 (32) 15.18 
East of 
England 3 (9) 5 (15) 2 (4) 4(9) 3 (8) 17 (9) 3.4 
England 33 33 49 45 36 196 3.92 
† Should not be interpreted as an estimate of incidence – see note on ascertainment, page 13.  
‡ The numerator for this indicator is incident cases in 2015-19, and the denominator is the summed mid-year 
estimate of the 0-15 population for 2017 multiplied by 4. Cases allocated to PHE Centre according to postcode of 
residence. 
* PHE Centres where an SAS laboratory that participates in the surveillance system is situated. 
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Figure 2. Graph showing detection rate of LEICSS cases per regional population of 0 to 
15 year olds, per million, 2015 to 2019, England 
 
 
* PHE Centres where an SAS laboratory that participates in the surveillance system is situated. 








Yorkshire and the Humber*
East of England
2015 2016 2017 2018 2019
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Figure 3. Average detection rate† of LEICSS cases (per million 0 to 15 year-old children) 
by PHE Centre, England 2015 to 2019 
 
† Should not be interpreted as an estimate of incidence – see note on ascertainment, page 13. 
 
Count and detection rate of cases by gender and age 
The majority of cases in 2019 were male (56%), lower than the 2015 to 2018 proportion (68%) 
(Table 4). Across all age groups the detection rate was higher in males than females (Figure 4). 
This gender disparity is also evident in some international survey findings [8] and may reflect a 
pre-disposition for males to behaviours or comorbidities that result in lead exposure (such as 
autism [14], itself associated with pica [15]), or a greater susceptibility to lead toxicity, and 
hence clinical presentation [16].  
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Table 4. Count and percentage of LEICSS cases by sex, England, 2019, and 2015 to 2018 
Sex Count of cases 2019 (%) Count of cases 2015 to 2018 (%) 
Female 16 (44) 45 (28) 
Male 20 (56) 109 (68) 
Unknown 0 (0) 6 (4) 
Total 36 160 
 
The highest case detection rate was in children aged 1 to 4 years in males and females (Figure 
4) 67% of cases were aged 1 to 4 years in 2019, slightly higher than the 4-year average (59%) 
(Table 5). Approximately a quarter of cases in 2019 were aged 5 to 11 years, slightly less than 
the 2015 to 2018 average (32%). There were a few cases in the youngest and oldest age 
groups; 3 cases were detected aged under 1 year in 2019. The high percentage of cases in pre-
school age children may reflect a greater vulnerability to lead exposure due to mouthing 
behaviours, as ingestion of lead containing substances (particularly from deteriorating paint) is 
likely to be the predominant route of exposure in children [2], and mouthing behaviour is 
common in this age group. Alternatively, children in this age group may be tested more 
frequently. For the adolescents, it is unknown what the common exposure sources are. They 
may be detected after exposure pathways other than pica are explored. 
 
Table 5. Count and percentage of LEICSS cases by age group*, England, 2019, and 
2015 to 2018 
 
Age group* Count of cases 2019 (%) Count of cases 2015 to 2018 (%) 
Under 1 year 3 (8) 6 (4) 
1 to 4 years 24 (67) 94 (59) 
5 to 11 years 8 (22) 51 (32) 
12 to 15 years 1 (3) 9 (5) 
Total 36 160 
* Age at date of entry onto HPZone. 
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Figure 4. Average case age-gender* specific detection rate† per million 0 to 15 year old 




* Age at date of entry onto HPZone. 
† The numerator for this indicator is the count of age-gender specific incident cases in 2015 to 2019, and the 
denominator is the summed mid-year estimate of the age-gender specific 0 to 15 year old population for 2017 
multiplied by 4.  
  
Percentage of cases by quintile of index of multiple deprivation (IMD) 
status 
IMD provides a measure of deprivation, evaluated across 7 domains7, measured at the area-
level. Eighty percent of cases in 2019 lived in areas in the 2 most deprived quintiles of IMD, 
higher than the previous 4-year average (70%) (Figure 5). This is higher than expected given 
that only 45% of the English population aged 0 to 15 years reside in areas falling within these 2 
quintiles8. These observations are similar to patterns of lead exposure by socioeconomic status 
in US national survey data [8], and may reflect greater exposure to lead containing hazards, a 
higher frequency of co-morbidities (for example, iron deficiency anaemia) or other factors pre-
disposing to lead toxicity, and/or a greater tendency for clinician testing of children from 
deprived areas.  
 
 
7 See: https://www.gov.uk/government/statistics/english-indices-of-deprivation-2019. 
8 Calculated using ONS mid-year estimate populations for England, assigned to deciles of IMD 2019.  
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Figure 5. Percentage of LEICSS cases in each quintile of index of multiple deprivation ¥, 
England 2019 and 2015 to 2018 
 
 
¥ Index of multiple deprivation (IMD) assigned to the Lower-level Super Output Area of the cases’ residential 
postcode, using IMD scores from 2019 
 
Blood lead concentrations of laboratory-detected 
cases 
The median blood lead concentration (BLC) in 2019 was 0.65 μmol/L(13.46 µg/dL), slightly 
lower than the 2015 to 2018 median (0.78 μmol/L(16.15 µg/dL)) (Table 6). Ninety-four percent 
(data not shown) of blood lead concentrations were <1.93μmol/L(<40 µg/dL) in 2015-2019, a 
concentration below which children would most likely be asymptomatic, or present with non-
specific neuro-behavioural clinical manifestations [1], indicating these children were detected 
based on high index of clinical suspicion. Three of the laboratory-detected cases reported to 
LEICSS in 2019 had blood lead concentrations <0.48 μmol/L(<10 µg/dL), these were excluded 





















% of cases 2019 % of cases 2015-18
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Table 6. Blood lead concentration (μmol/L) of laboratory detected LEICSS cases, 






Minimum* Maximum Median Lower Quartile 
Upper 
Quartile Mean 
2019 30/30 0.48 1.89 0.65 0.50 1.16 0.83 
2015 to 
2018 129/129** 0.48 3.30 0.78 0.56 1.15 1.09 
* Only children with a BLC≥0.48μmol/L were eligible for notification to LEICSS 
** Includes 4 HPZone-detected cases subsequently reported to LEICSS by participating laboratories with blood 
lead specimen dates prior to or on the same day as date of report to PHE HPTs.  
 
Children whose death was attributed to lead 
exposure 
This information is taken from data extracted from the PHE HPZone case management system 
to the LEICSS dataset. Only deaths attributed partly or wholly to lead exposure are shown, and 
only in cases that meet the LEICSS case definitions. Case information was also corroborated 
with the investigating HPT. In the period of 2015 to 2019, PHE HPTs recorded 1 death in a child 
in England (2015), partly or wholly attributed to lead exposure. A case report has since been 
published, showing the death occurred in a two-year-old boy with pica and iron deficiency who 
had ingested lead-containing paint, resulting in acute lead toxicity [13]. Lack of clinician 
awareness of the association between pica and lead exposure was cited as a root cause of the 
delayed diagnosis and subsequent death of the child [13]. Previous research has shown deaths 
from lead exposure in children to be very infrequent in England [17]. 
 
Duration of case investigation 
Of the cases where the investigation had been concluded by the time of data extraction for this 
report (81%, January 2020), the median duration of the investigation was 7 weeks, considerably 
shorter than the median for 2015 to 2018 (Table 7). To some extent, this reduction in the 
duration can be explained by the greater percentage (19%) of 2019 cases compared to 2015 to 
2018 (5%) that remained open at the time of data extraction (and likely therefore to eventually 
record longer duration of investigation). The reduction could also reflect improvements in case 
management in 2019 but it is not possible to conclude this at this time.  
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Table 7. Duration, in weeks, of the public health investigation of LEICSS cases* reported 
to the surveillance system, England, 2019, 2015 to 2018 
 
Year Closed cases/Total cases (%) Median duration (weeks)* (LQ-UQ) 
2015 to 2018 152/160 (95%) 15 (5-38) 
2019 29/36 (81%) 7 (3-10) 
* Period between date entered onto HP Zone and date case closed on HPZone; cases must have been closed at 
date of data extraction from HPZone in January 2020; LQ – Lower Quartile; UQ – Upper Quartile.  
 
System developments 
Progress on developing surveillance of lead cases has continued in 2020. PHE’s major efforts 
in health protection has focused on responding to the COVID-19 global pandemic. We have 
continued to respond to cases reported to PHE, but developments in surveillance functions 
have been delayed.  
 
Public health intervention level for lead 
The public health intervention level for lead has been lowered over time to reflect both the 
gradual decline in population exposure, and the changing knowledge that lead exposure in 
children is associated with toxicity at very low blood concentrations. We now know that lead 
exposure is associated with neuro-behavioural impairments at blood concentrations of 
0.24μmol/L (5μg/dl) and even lower [1,18]. Lowering the intervention level for lead would follow 
international precedent set by recommendations in the USA [19], Australia [20], Germany [21], 
France [22] and Wales [23], and would offer benefits of case management to more affected 
children and communities. An evaluation conducted by PHE in 2018 recommended that the 
public health intervention level for lead be lowered from ≥10μg/dL (≥0.48μmol/L) to ≥5μg/dL 
(≥0.24μmol/L) in England and should apply to children aged up to and including 15 years, and 
to pregnant women. This recommendation is based on estimates in pre-school children who 
have the highest BLCs, to maximise the specificity to detect children most likely to benefit from 
public health action. The evaluation concluded that lowering the intervention level for lead to 
≥5μg/dL (≥0.24μmol/L) would identify children with a BLC in the top 2% of the population range 
and would have a net positive impact on health inequalities. Analysis from UK SAS laboratories 
data estimated that lowering the intervention level for lead to ≥5μg/dL (≥0.24μmol/L) would 
result in a 2 to 3-fold increase in case notification to PHE in the short- to medium- term 
(provided that there is no change in other factors influencing case notification); this should 
represent only a small absolute increase in the number of notifications to a single HPT. This 
would harmonise the public health invention level across England, Wales and Scotland. In 
2019, 8 cases with a BLC under <10μg/dL (<0.48μmol/L) were reported to PHE for public health 
management (3 reported from participating labs, 5 reported via other routes). Although the BLC 
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was lower than the case definition, these cases were actively followed up. by the health 
protection teams. A working group was set up to coordinate communication of the new 
intervention level to stakeholders and update the lead action card, guidance for practitioners 
and clinicians, and LEICSS documentation. It is anticipated that the new public health 
intervention level for lead will apply early in 2021. An intervention level for lead of ≥10μg/dL 
(≥0.48μmol/L) for non-pregnant adults will remain. 
 
Invitation of further laboratories to participate in surveillance 
We wrote to laboratories in the UK National External Quality Assessment Scheme for Trace 
Elements (which includes measurement of blood lead concentration) in 2018 to invite them to 
participate in case reporting to LEICSS; Resulting from this invitation, 7 new laboratories have 
agreed to participate (Bristol Southmead, Alder Hey, Royal Liverpool, Northern General 
(Sheffield), Wakefield, Birmingham Heartlands and the private Doctors Laboratory (London)). 
Other UKAS accredited laboratories testing for child BLC are also welcome to participate.  
 
Governance and procedures 
Following implementation of a permanent surveillance system in 2016 and in accordance with 
the governance framework for other PHE surveillance systems, a data sharing agreement was 
introduced with participating laboratories and a new case notification form was issued in 2018. 
The data sharing agreement is being reviewed to ensure full compliance with GDPR 
requirements. New procedures were also introduced to enter laboratory data onto HPZone and 
extract it for analysis which reduced the requirement to maintain a separate laboratory dataset. 
Standard Operating Procedures for the surveillance were also drafted and updated.  
 
Alerts for testing for blood lead 
Introduction of an alert on the electronic test request system by Leeds SAS laboratory to 
encourage clinicians to consider testing for blood lead (for those children suspected of pica or 
iron deficiency) increased test requests by 90% since 2017. We will work with other laboratories 




Information on exposures in children with elevated BLC is currently captured through a 
questionnaire completed by HPTs on paper or as an electronic document which is uploaded to 
HPZone. This questionnaire has been converted into an online survey format to help HPTs 
explore and scope exposure information and collect relevant information for surveillance. It is 
intended that the new online questionnaire will go live at the same time as the public health 
intervention level is lowered. The questionnaire for initial case management helps the 
practitioner to explore potential sources of lead. This information will enable us to scrutinise 
exposure sources for surveillance purposes [11]. 
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PHE’s Environmental Public Health Surveillance System 
The Environmental Public Health Surveillance System (EPHSS) collates and integrates data 
from selected databases on environmental hazard, exposures and health outcome data; further 
details are provided on the PHE website. A lead exposure in children module incorporated into 
EPHSS allows for LEICSS data to be interrogated and analysed, producing user defined 
outputs for surveillance reporting purposes. Currently, the EPHSS platform is available to PHE 
staff, but will shortly become accessible to external users.  
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Current and future research and projects 
The SAS laboratory network have requested further guidance on repeat testing of BLC in 
children who are already under investigation for elevated blood lead concentrations. We are 
working with the National Poisons Information Service (NPIS) to develop additional guidance 
documents aimed at supporting the management of children with lead exposure. 
 
The Environmental Epidemiology Group at CRCE is working to produce hazard maps for soil 
lead concentration, housing age and index of multiple deprivation to develop a lead exposure 
model. 
 
The LEICSS working group, with The British Paediatric Surveillance Unit (BPSU) and Royal 
College of Paediatrics and Child Health are planning to present a webinar on lead as part of 
their series on rare diseases (to raise awareness of LEICSS amongst clinicians). 
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The PHE working group tasked with reviewing the proposed lowering of the blood-lead 
intervention level appraised the service impact, resource implications and guidance required. 
Stakeholder engagement is underway to ensure a smooth implementation of the new public 
health blood-lead intervention level. 
 
The lead exposure questionnaire in use by HPTs to support initial case management has been 
reviewed and updated to better scope and capture potential exposures in cases reported to 
PHE. 
 
The LEICSS team are developing case studies that can be used by SAS labs for staff education 
and training. 
 
The LEICSS steering group has widened the range of stakeholders who are consulted or 
communicated with for surveillance and management of paediatric lead exposure cases. 
 
PHE is working with the Georgian National Centre for Disease Control on a research project to 
identify sources of lead exposure in children. Lead isotope analysis is being used to match 
blood lead and environmental lead in spices, food, milk, water, soil, dust and toys as part of a 
prevalence study. 
 
Implementation of recommendations since publication of the Annual 
Reports9 
The following recommendations made in previous annual reports have been actioned and 
progressed (with current progress).  
 
LEICSS steering and working group 
For the LEICSS steering and working group to: 
 
Task 
Introduce a new case notification form and data sharing agreement with laboratories, and new 
procedures to record laboratory data directly into HPZone and extract it for analysis. These 
measures should improve laboratory data recording quality.  
 
Progress 
Further to this recommendation, case notification forms were updated. Data sharing 
agreements have been signed with most laboratories and are in the process of being updated. 




9 As mentioned in the introduction to this report, plans for further implementation have been delayed due to the 
demands on PHE staff to respond to the COVID pandemic. 
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Introduce methods to extract and collate information from the detailed exposure questionnaires 
conducted on lead exposure cases by investigating HPTs, in order to collect and analyse data 
on other potentially important case factors.  
 
Progress 
Further to this recommendation, a new online questionnaire was developed to help HPTs 
investigate potential exposures and to capture exposure information in greater detail. This 
improvement will make it easier to extract, analyse and summarise surveillance information. We 
plan to undertake an evaluation exercise to review sources of exposure in all cases captured by 
the system so far. 
 
Task 
Survey participating laboratories as to whether they offer laboratory-based systems to prompt 
clinicians to test for lead exposure in children, or undertake awareness raising activities in their 
area, for example as implemented in Leeds SAS laboratory [13].  
 
Progress 
Further to this recommendation, we have joined forces with the SAS Lab network to identify and 
identify best practices for guidance, and to support the roll out of new alerting systems that are 
currently being planned. 
 
Task 
Continue to encourage further laboratories to participate in the surveillance system. 
 
Progress 
Further to this recommendation, we wrote to laboratories in the UK National External Quality 
Assessment Scheme for Trace Elements (which includes measurement of blood lead 
concentration) to invite them to participate in case reporting to LEICSS; As a result, 7 new 
laboratories have agreed to participate and are now reporting into the surveillance system. 
 
Task 
Consider the evidence and arguments for lowering the public health intervention level for lead 
and laboratory reporting BLC to ≥0.24μmol/L (5μg/dl). 
 
Progress 
Further to this recommendation, a PHE working group was formed in 2018 to review the 
evidence for lowering the intervention level for lead. This work has yielded new proposals to 
lower the intervention level which are now being finalised. This includes more detailed guidance 
for PHE advice in managing cases and referral to NPIS for clinical advice. Stakeholder 
communication activities are currently being conducted.  
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Task 
Share the findings of this report with the Royal College of Paediatrics and Child Health, and the 
Royal College of General Practitioners to raise awareness amongst paediatricians and GPs.  
 
Progress 
Further to this recommendation, the report was sent to these stakeholder networks. Further 
communication with the RCPCH and other key networks continue to take place.  
 
Task 
Develop a broader group of consulting stakeholders including clinical and lay (parent and 
guardian) representatives.  
 
Progress 
Further to this recommendation, a stakeholder mapping exercise was conducted, and new 
stakeholders were identified. A consultation and distribution list are continuously updated and 
used to communicate about lead exposures. 
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For the LEICSS steering and working group 
These groups should: 
 
• work with the SAS laboratory network to explore implementation of an alert on the 
electronic test request system to prompt clinicians to consider blood lead testing 
based on the model introduced at Leeds SAS laboratory [13] 
• support the work to reduce the public health blood-lead intervention level to ≥5μg/dL, 
for children and pregnant women 
• continue to encourage further laboratories to participate in the surveillance system 
• audit the procedure for managing lead exposure laboratory reports to monitor and 
maintain data quality 
• share the findings of this report with the Royal College of Paediatrics and Child 
Health, and Royal College of General Practitioners to raise awareness amongst 
paediatricians and GPs 
• make recommendations to support a survey into the current prevalence of elevated 
blood lead concentration in children in England, to include a multidisciplinary proposal 
including population prevalence, economic evaluation and exposure assessment 
• support PHE to establish a dedicated lead poisoning prevention information service 
including web site material and public information leaflets  




• participating laboratories should always notify cases to LEICSS by emailing the case 
notification form to phe.leicss@nhs.net  
• laboratories interested in participating in the surveillance system should also email 
phe.leicss@nhs.net to express their interest 
• participating laboratories should be aware that PHE will advise when the new lower 
public health intervention level for lead of ≥5μg/dL (≥0.24μmol/L) for children under 16 
years and pregnant women will apply and when to notify cases at the lower level 
• laboratories should notify all blood lead concentration results to the requesting 
clinician 
 
For PHE Health Protection Teams 
HPTs should: 
 
• be aware that there is likely a large regional variation in clinician awareness, testing 
and reporting practice for lead exposure in children 
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• determine which laboratories test for lead exposure in children in their population, and 
whether the laboratory participates in lead surveillance reporting 
• share this report with local paediatricians and GPs to raise awareness of sources of 
lead exposure, children at most risk, and presenting symptoms or signs of exposure 
(see box below) 
• be aware that the public health intervention level for lead will be lowered from 
≥10μg/dL (≥0.48μmol/L) to ≥5μg/dL (≥0.24μmol/L) for children and pregnant women; 
a briefing note will be issued to communicate when this change will be implemented.  
• encourage clinicians to notify them of children with BLC at or above the public health 
intervention level for lead 
• it would be advantageous for a clinical interest group with health promotion and 





• be aware that there is no safe blood lead concentration for children 
• be aware of the most important sources of lead exposure in children (see box 1, 
below) 
• be aware of the children at most risk of lead exposure (see box 1, below), and have a 
low threshold for screening these children for lead exposure if they may have been 
exposed to lead hazards 
• educate parents or guardians of children at risk about prevention of lead exposure, 
through the provision of information leaflets and so on 
• consider lead exposure as a potential diagnosis in children presenting with symptoms 
or signs of acute or chronic lead exposure (see box 1, below)  
• follow PHE and NPIS guidance for managing cases of lead exposure in children 
• be aware of PHE’s role in managing cases, how to report a case, and of the case 
management and surveillance benefits of reporting cases to PHE 
• refer to the Other Resources section, below, for details of how to report a case of lead 
exposure, and for resources offering further guidance on case management 
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Box 1. Sources of lead exposure in children, children at most risk of exposure, and 
presentations of lead exposure in children 
 
 
Important sources of lead exposure in children 
 
• deteriorating leaded paint (particularly houses built prior to early 1970s) 
• herbal medicinal preparations 
• consumer products (if unregulated): medicines, food, spices, ceramic 
cookware, toys, make-up 
• parental hobbies or occupations (including dust on clothing) 
• lead water pipes, and lead from drinking water pipe fittings (namely, solder) 
(particularly houses built prior to early 1970s) 
• contaminated soil or land 
 
Children at most risk of lead exposure 
 
• children with pica or increased hand to mouth behaviour (for example, 
children with autism or global developmental delay), particularly with iron 
deficiency 
• children who have recently migrated from countries with less regulation to 
prevent lead exposure 
• children living in older homes and attending older schools containing leaded 
paint 
• children living in more urban or industrial environments 
 
Presentations of lead exposure in children 
 
• acute exposure resulting in high BLC: anorexia, abdominal pain, constipation, 
irritability and reduced concentration, encephalopathy 
• chronic exposure [24] 
• lower BLCs - mild cognitive and behavioural impairments, may contribute to 
global developmental delay, decreased academic achievement, IQ, and 
specific cognitive measures (S); increased incidence of attention-related 
behaviours and problem behaviours (S), and delayed puberty and decreased 
kidney function in children ≥12 years of age (L). 
• higher BLCs - reduced appetite, abdominal pain, constipation, anaemia, 
delayed puberty, reduced postnatal growth, decreased IQ, and decreased 
hearing (S); and increased hypersensitivity or allergy by skin prick test to 
allergens and increased IgE (L). 
 
(S) = sufficient evidence and (L) = limited evidence 
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Further PHE resources for the public health management of cases of lead exposure: 
 
• Lead pages in the PHE chemicals compendium  
• Lead Action Card (PHE internal only, will be updated in line with the new intervention 
level) 
• Lead Exposure in Children Surveillance System: Surveillance Reports 
 
Resources for clinicians 
• clinicians with clinical lead exposure queries should consult TOXBASE or call the 
National Poisons Information Service 
 
Contacts 
• to notify cases (participating labs only): phe.leicss@nhs.net   
• general enquiries: epht@phe.gov.uk 
• lead surveillance module in PHE’s Environmental Public Health Surveillance System: 
ephss@phe.gov.uk 
• to notify cases (direct to a Health Protection Team) find the relevant Health Protection 
Team using the residential postcode of the case  
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